Since 1991, the “315 Evening Gala” (World Consumer Rights Day Conference) has been held for 34 consecutive years and is currently the most talked-about event among the Chinese people and the most highly anticipated show for businesses, apart from the Spring Festival Gala broadcasted by CCTV. Each edition of “315” focuses on exposing the hidden rules in consumer life that are unknown to the public and revealing numerous dark secrets of consumer deception.
Due to the unique nature of the “315 Evening Gala,” many companies not only try to avoid appearing in the show in various ways but also rarely choose to make appearances or statements during this time period.
As a global leader in the field of recombinant collagen protein, Giant Biogene has bravely turned inward and willingly accepted the scrutiny and amplification that comes with the “315” event. They are determined to contribute to the healthy development of the industry. Giant Biogene, in collaboration with Xinhua Net and other media outlets, has released the “Giant Biogene’s 3.15 Transparent Commitment.” They have also announced their commitment to continue not directly selling raw materials of recombinant collagen protein to the public in the coming year, ensuring strict control over the source of the industry and taking the lead in entering the era of transparent consumption of recombinant collagen protein components.
Four Transparent Commitments
Recombinant Collagen Protein Enters the Era of Transparent Consumption
In recent years, the rapid development of recombinant collagen protein has been evident, as it has quickly risen to become a “new favorite” in the ingredient field. Under the trend, not only upstream suppliers but also leading beauty companies and brands from both domestic and international markets have actively entered the industry. Additionally, cross-industry players in the recombinant collagen protein sector are also becoming increasingly common.
Data also confirms the popularity of the recombinant collagen protein track. According to Frost & Sullivan, the market size of recombinant collagen protein in China is projected to grow from 10.8 billion RMB in 2021 to 108.3 billion RMB in 2027, with a penetration rate reaching 62.3% in the collagen protein field. The future growth rate is promising.
However, the emergence, growth, and expansion of any new phenomenon will inevitably face relevant challenges, and while the recombinant collagen protein industry is developing rapidly, it is necessary to acknowledge the existing imperfections in the industry.
How can the recombinant collagen protein industry become more standardized? Moreover, how can consumers clearly distinguish the components of recombinant collagen protein?
At this year’s “315” event, Giant Biogene courageously took a step forward and, in collaboration with Xinhua Net and other media outlets, released the “Giant Biogene’s 3.15 Transparent Commitment.” This action aims to protect consumer rights while guiding the industry towards orderly and healthy development, avoiding unnecessary detours.
Furthermore, CHAILEEDO has learned that every box of Giant’s Kefumei Collagen Bar (regular product) produced after March 15, 2024, will gradually be accompanied by a “Transparency Commitment Statement.”
It is worth noting that on the day of “315,” Giant Biogene also released the 315 Transparent Commitment TVC. In the promotional video, swimming world champion and brand ambassador for Kefumei Essence, Ye Shiwen, senior lawyer Liu Siyuan, and veteran media professional Zhang Chun jointly speak about the “Giant Biogene’s 3.15 Transparent Commitment.”
Behind the “Giant Biogene’s 3.15 Transparent Commitment,” it is evident that by transparently sharing information regarding the origin, classification, source, and content, it facilitates consumer understanding and supervision. This not only showcases the brand’s confidence but also demonstrates the company’s sense of responsibility. For the recombinant collagen protein industry, it marks a step towards the era of transparent consumption.
Upholding Responsibility with Professionalism, Ensuring the Integrity of the Industry’s Source
Under the principle of “altruistic thinking,” a company that values consumer rights protection and actively assumes industry missions and responsibilities undoubtedly achieves long-term development. In his advocated “Six Principles of Improvement,” Inamori Kazuo, the “Saint of Management” in Japan, emphasized the importance of “altruism and benefiting others.” In his view, “altruism is the highest form of business model, and when running a business, one must genuinely seek to benefit others.”
With over 20 years of deep involvement in the recombinant collagen protein industry, Giant Biogene is a practitioner of “altruistic thinking.” It not only consistently fulfills the responsibilities of an industry leader but also strives to provide consumers with more efficient and distinctly Chinese ingredients and products. As mentioned by the relevant person in charge of Giant Biogene, “What Giant Biogene has always wanted to do is to be a responsible company for the people and to assume social responsibilities.”
In fact, the aforementioned “Giant Biogene’s 3.15 Transparent Commitment” is just one declaration made by Giant Biogene on “315.” In addition, it formally announced that it will continue to refrain from directly selling recombinant collagen protein raw materials to the public in the coming year, ensuring the integrity of the industry’s source and effectively protecting consumer interests through concrete actions.
It is well-known that collagen protein accounts for 70% of the dry matter in human skin. With its advanced reparative, stabilizing, regenerative, and anti-aging effects, recombinant collagen protein has become the core ingredient of the new generation of biocosmetics. As a hard-tech benchmark enterprise supported by the Ministry of Science and Technology, Giant Biogene’s move undoubtedly reduces the industry’s speculative concepts and excessive marketing. It not only safeguards the healthy development of recombinant collagen protein but also preserves consumers’ confidence in the ingredients.
From the current perspective, CHAILEEDO has learned that Giant Biogene is among the first companies in the recombinant collagen protein industry to explicitly make the aforementioned commitments.
In fact, Giant Biogene has always demonstrated industry responsibility through professional practice. For example, many years ago, Giant Biogene incurred losses of 50 million RMB for a total of nine consecutive years, with the company’s funds only able to sustain it for six months at most. In the seventh year of losses, an international skincare brand offered to purchase Giant Biogene’s recombinant collagen protein technology patents for a price between 80 million and 100 million US dollars. However, this proposal was firmly rejected.
“The international brand wanted to buy our patents because they didn’t want any strong competitors in the industry,” recalled the person in charge of Giant Biogene. “If the patents were sold, we couldn’t guarantee whether the international brand would continue to develop this ingredient properly. Some people only saw the high price, but the scientists in the Giant Biogene team saw the value of recombinant collagen protein for human health. Therefore, we ultimately decided that no matter how difficult it may be, we must thoroughly research this ingredient.”
“At this special ‘315’ moment, it is not easy for Giant Biogene to speak out. The two declarations they have made will promote a healthier development of the industry and enable consumers to have a better understanding of the ingredients of recombinant collagen protein. As a result, they can choose brands or companies that are dedicated to producing quality products and ingredients,” commented an industry expert.
Attaining Authoritative Certification, Standing at the Forefront of the Global Market
For over 20 years, Giant Biogene has tirelessly cultivated numerous achievements from 0 to 1: from pioneering technology to mass production, from brand incubation to expanding its territory. By speaking out and contributing to the industry’s development, its position as an industry leader is self-evident.
Recently, Euromonitor International issued a declaration of Giant Biogene’s global leadership position in the recombinant collagen protein market. Euromonitor International, a well-established British research institution with a 52-year history, has become a leading provider of strategic market information worldwide. Its team of industry experts, stationed in 80 countries around the globe, can deeply analyze various cutting-edge trends in today’s international business landscape, ensuring the authority of its research on a global scale.
For Giant Biogene, becoming a global leader in recombinant collagen protein is primarily due to its research and innovation capabilities. Public information shows that Giant Biogene has developed significant advantages in recombinant collagen protein research, including the “most” in terms of variety, length, and shortness. The Giant Biogene molecular library not only possesses over 40 types of recombinant collagen protein reserves but is also the only domestic enterprise capable of producing full-length single-chain recombinant collagen protein. Additionally, it has the smallest molecular weight recombinant collagen protein peptide in the industry, which has been clinically proven to have excellent transdermal absorption capabilities.
Furthermore, Giant Biogene has established the most comprehensive recombinant collagen protein expression system to date. It has independently developed intellectual property rights in the three mainstream recombinant collagen protein expression systems: Pichia pastoris, Saccharomyces cerevisiae, and Escherichia coli. It is worth mentioning that the purity of the recombinant collagen protein produced by Giant Biogene can reach 99.9%, meeting the industry standards for medical-grade materials. It is also one of the companies with the highest recombinant collagen protein production capacity globally.
Looking back at the “History of China’s Recombinant Collagen Protein Development” (note: published jointly by Artery Network and Cosmetics News), before 2014, Giant Biogene’s development history was almost synonymous with the development history of China’s recombinant collagen protein industry. From its founding team of 50 people to overcoming key technologies, it eventually rose to the forefront of science and technology. Since 2014, the recombinant collagen protein industry has witnessed the emergence of many capable enterprises such as Jinbo Bio., Trautec, and Jland, shining brightly.
With an increasing number of players entering the industry, the recombinant collagen protein industry urgently needs standardization. Therefore, in the past two years, Giant Biogene, as one of the drafting units, has actively participated in the formulation of the Chinese pharmaceutical industry standards YY/T1849-2022 “Recombinant Collagen Protein” and “Technical Requirements for Collagen Protein Raw Materials in Cosmetics.” Among them, YY/T1849-2022 “Recombinant Collagen Protein” is one of the highest-level and most comprehensive industry standards to date, officially implemented on August 1, 2022.
Now, with the release of the “Giant Biogene’s 3.15 Transparent Commitment,” Giant Biogene once again demonstrates its responsibility and commitment as an industry pioneer, striving to promote a more transparent and standardized future for the recombinant collagen protein industry. By steadfastly exploring and positioning themselves at the forefront of the industry, Giant Biogene has validated its position and influence as a global leading brand.
